BioXcel Therapeutics, Inc. Cost of Revenue
BioXcel Therapeutics, Inc. (BTAI) reported Cost of Revenue of $22.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-13
- BioXcel Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $22.00K, a 79.44% decline year-over-year.
- BioXcel Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $283.00K, a 1921.43% increase year-over-year.
- BioXcel Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $32.00K, a 96.15% decline year-over-year.
- BioXcel Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $11.00K, a 99.06% decline year-over-year.
- BioXcel Therapeutics, Inc. cost of goods and services sold for fiscal 2025 was $164.00K, a 92.35% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. cost of goods and services sold for fiscal 2024 was $2.14M, a 70.08% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. cost of goods and services sold for fiscal 2023 was $1.26M, a 6200.00% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. cost of goods and services sold for fiscal 2022 was $20.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-13 | $305.00K 10-Q · filed 2026-08-13 | $337.00K derived: sum of 3 quarters · filed 2026-08-13 | $348.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $283.00K 10-Q · filed 2026-05-15 | $315.00K derived: sum of 2 quarters · filed 2026-05-15 | $326.00K derived: sum of 3 quarters · filed 2026-05-15 | $433.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $43.00K derived: sum of 2 quarters · filed 2026-03-27 | $150.00K derived: sum of 3 quarters · filed 2026-08-13 | $164.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $11.00K 10-Q · filed 2025-11-12 | $118.00K derived: sum of 2 quarters · filed 2026-08-13 | $132.00K 10-Q · filed 2025-11-12 | $964.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $107.00K 10-Q · filed 2026-08-13 | $121.00K 10-Q · filed 2026-08-13 | $953.00K derived: sum of 3 quarters · filed 2026-08-13 | $2.12M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-15 | $846.00K derived: sum of 2 quarters · filed 2026-05-15 | $2.02M derived: sum of 3 quarters · filed 2026-05-15 | $2.08M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $832.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.00M derived: sum of 2 quarters · filed 2026-03-27 | $2.06M derived: sum of 3 quarters · filed 2026-03-27 | $2.14M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.17M 10-Q · filed 2025-11-12 | $1.23M derived: sum of 2 quarters · filed 2025-11-12 | $1.31M 10-Q · filed 2025-11-12 | $2.03M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $62.00K 10-Q · filed 2025-08-12 | $141.00K 10-Q · filed 2025-08-12 | $856.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.37M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $80.00K 10-Q · filed 2025-05-12 | $794.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.31M derived: sum of 3 quarters · filed 2025-05-12 | $1.33M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $714.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.23M derived: sum of 2 quarters · filed 2025-03-28 | $1.25M derived: sum of 3 quarters · filed 2025-03-28 | $1.26M 10-K · filed 2025-03-28 |
| 2023-09-30 | $512.00K 10-Q · filed 2024-11-14 | $538.00K derived: sum of 2 quarters · filed 2024-11-14 | $546.00K 10-Q · filed 2024-11-14 | $556.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $26.00K 10-Q · filed 2024-08-06 | $34.00K 10-Q · filed 2024-08-06 | $44.00K derived: sum of 3 quarters · filed 2024-08-06 | $55.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $9.00K 10-Q · filed 2024-05-09 | $18.00K derived: sum of 2 quarters · filed 2024-05-09 | $29.00K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $20.00K derived: sum of 2 quarters · filed 2024-03-22 | $20.00K 10-K · filed 2024-03-22 | |
| 2022-09-30 | $11.00K 10-Q · filed 2023-11-14 | $11.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |